Invoking Learned Intermediary Rule in Malaysia

Abstract

In the realm of pharmaceutical liability, failure to warn or to provide sufficient information such as adverse reaction or allergies of pharmaceutical products may cause manufacturers to be liable under the traditional common law of tort for the harm or death it causes. This article shows that manufacturers of prescribed pharmaceutical products may escape such liability if information and warnings have been conveyed to physicians; a learned intermediary between the manufacturers and the patients. The learned intermediary rule acts as a defence mechanism for manufacturers of pharmaceutical products as the physician is deemed as an intervening force that breaks the chain of causation in the law of negligence. Hence, the main focus of this article is to examine whether Malaysian courts would accept such a defence if invoked by the manufacturers. The objective of the article is to analyze and identify the learned intermediary between the manufacturer of a prescribed pharmaceutical products and patients under the relevant Malaysian statutes, particularly Poison Act 1952 and Medicines

A Framework for Estimating Piping Reliability Subject to Corrosion Under Insulation

“…The variability of the random variables S, CR, P, D and t is reviewed and estimation of their probability distributions and their parameters are made. Ref [4,6] shows the details of how the analysis is being done.…”

“…A three-state Markov model for general wall thinning proposed by Fleming [6] is employed in this study, as shown in Figure 2. The state transition rates are denoted by ϕ, λ and ω. Fleming defined the three states; State 1 (no detectable damage), State 2 (detectable flaw (wall thinning) and State 3 (failure i.e.…”